ES2421516T3 - Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341 - Google Patents

Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341

Info

Publication number
ES2421516T3
ES2421516T3 ES03768749T ES03768749T ES2421516T3 ES 2421516 T3 ES2421516 T3 ES 2421516T3 ES 03768749 T ES03768749 T ES 03768749T ES 03768749 T ES03768749 T ES 03768749T ES 2421516 T3 ES2421516 T3 ES 2421516T3
Authority
ES
Spain
Prior art keywords
compositions
treating cancer
proteasome inhibitor
monotherapy
sensitivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03768749T
Other languages
English (en)
Inventor
Kenneth Anderson
Teru Hideshima
Constantine Mitsiades
Nicholas Mitsiades
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32312799&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2421516(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2421516T3 publication Critical patent/ES2421516T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de una cantidad eficaz de PS-341, para la preparación de un medicamento para aumentar lasensibilidad de una célula cancerosa derivada de un sujeto que experimentó recidiva tras la monoterapiacon P S-341, un agente quimioterápico.
ES03768749T 2002-11-06 2003-11-06 Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341 Expired - Lifetime ES2421516T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42436302P 2002-11-06 2002-11-06
PCT/US2003/035513 WO2004043374A2 (en) 2002-11-06 2003-11-06 Methods and compositions for treating cancer using proteasome inhibitors

Publications (1)

Publication Number Publication Date
ES2421516T3 true ES2421516T3 (es) 2013-09-03

Family

ID=32312799

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03768749T Expired - Lifetime ES2421516T3 (es) 2002-11-06 2003-11-06 Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341

Country Status (7)

Country Link
US (2) US8026230B2 (es)
EP (1) EP1565193B1 (es)
JP (2) JP5354836B2 (es)
AU (1) AU2003291356A1 (es)
CA (1) CA2504933C (es)
ES (1) ES2421516T3 (es)
WO (1) WO2004043374A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
JP5354836B2 (ja) * 2002-11-06 2013-11-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド プロテアソームインヒビターを使用する癌を処置するための方法および組成物
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
KR20060026052A (ko) 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법
CN1823070A (zh) 2003-06-20 2006-08-23 加利福尼亚大学董事会 盐孢菌酰胺及其使用方法
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
JP2007535559A (ja) 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びその使用法
DE602005019156D1 (de) * 2004-05-26 2010-03-18 Anima Cell Metrology Verfahren zur auswertung von ribonukleotidsequenzen
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
JP2008522975A (ja) * 2004-12-03 2008-07-03 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びそれらのアナログを使用する方法
CA2588923C (en) 2004-12-03 2015-02-03 Kenneth C. Anderson Compositions and methods for treating neoplastic diseases
AU2006226861B2 (en) 2005-03-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
WO2006101535A1 (en) * 2005-03-23 2006-09-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of proteasome function to potentiate the proapoptotic and antitumor activity of cytokines
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
BRPI0707826B1 (pt) * 2006-02-14 2022-04-19 Dana-Farber Cancer Institute, Inc. Compostos inibidores de histona desacetilase, composição farmacêutica e uso dos referidos compostos
AU2007248656B2 (en) * 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
US7824698B2 (en) 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
WO2008121442A2 (en) * 2007-02-09 2008-10-09 The Uab Research Foundation Pa28-gamma regulation in cells
US20100292129A1 (en) * 2007-05-24 2010-11-18 Daniel Finley Methods and Compositions for Enhancing Proteasome Activity
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
WO2009140287A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
US8440716B2 (en) 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
JP2012508749A (ja) * 2008-11-13 2012-04-12 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 多発性骨髄腫治療のためのベンダムスチン、ドキソルビシンおよびボルテゾミブの併用
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
WO2011036666A2 (en) * 2009-09-24 2011-03-31 Anima Cell Metrology, Inc. Systems and methods for measuring translation of target proteins in cells
EP3388060A1 (en) * 2012-10-22 2018-10-17 Arnold Glazier Methods for the effective treatment of metastatic cancer
US20160022757A1 (en) * 2013-03-15 2016-01-28 Icahn School Of Medicine At Mount Sinai Therapeutic methods for treating solid tumors and related diagnostic methods
US20160113911A1 (en) * 2013-06-06 2016-04-28 The General Hospital Corporation Methods and compositions for the treatment of cancer
AU2016276563A1 (en) * 2015-06-11 2018-01-04 One World Cannabis Ltd Novel cannabinoid combination therapies for multiple myeloma (MM)
WO2017083741A1 (en) * 2015-11-13 2017-05-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Proteasome modulation for treatment of corneal disorders
IL290251B1 (en) 2015-12-07 2024-03-01 General Oncology Inc Combination for effective treatment of metastatic cancer in patients
MX2018016387A (es) 2016-06-29 2019-09-09 Kezar Life Sciences Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona.
EP3478669B1 (en) 2016-06-29 2023-08-30 Kezar Life Sciences Process of preparing a peptide epoxyketone immunoproteasome inhibitor
WO2018102317A1 (en) * 2016-11-29 2018-06-07 The Regents Of The University Of California Modulation of p53 for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
JP2701932B2 (ja) 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
AU661270B2 (en) 1990-03-05 1995-07-20 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
DE4023465A1 (de) 1990-07-24 1992-02-06 Andrae Hans Peter Turmbauwerk
WO1992012140A1 (en) 1990-12-28 1992-07-23 Georgia Tech Research Corporation Peptides ketoamides, ketoacids, and ketoesters
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US20020041874A1 (en) * 1998-09-14 2002-04-11 The Board Of Regents, University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CA2362426A1 (en) * 1999-02-10 2000-08-17 Takashi Tsuruo Anticancer drug enhancer
EP1210118B1 (en) 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
US20020049157A1 (en) * 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
JP5354836B2 (ja) * 2002-11-06 2013-11-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド プロテアソームインヒビターを使用する癌を処置するための方法および組成物

Also Published As

Publication number Publication date
EP1565193A4 (en) 2008-05-21
JP2007224053A (ja) 2007-09-06
CA2504933A1 (en) 2004-05-27
AU2003291356A8 (en) 2004-06-03
WO2004043374A2 (en) 2004-05-27
US20050267037A1 (en) 2005-12-01
AU2003291356A1 (en) 2004-06-03
JP5354836B2 (ja) 2013-11-27
JP2006509746A (ja) 2006-03-23
CA2504933C (en) 2012-10-16
US20120214757A1 (en) 2012-08-23
EP1565193A2 (en) 2005-08-24
EP1565193B1 (en) 2013-04-24
US8685954B2 (en) 2014-04-01
WO2004043374A3 (en) 2004-08-12
US8026230B2 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
ES2421516T3 (es) Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
UY28342A1 (es) Nuevos compuestos
UY27740A1 (es) Nuevos compuestos
CL2008002687A1 (es) Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico.
UY26496A1 (es) Composiciones farmacéuticas que proporcionan concentraciones potenciadas de fármaco
CR8428A (es) Agente endoparasiticidas para la administracion topica
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
UY27720A1 (es) Aroilpiridinonas monocíclicas,
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
ES2377720T3 (es) Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
CR8673A (es) Compuestos de difenil-ox-indol-2-ona y su uso en el tratamiento del cancer
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
UY28014A1 (es) Compuestos quimicos
TW200744568A (en) Epinephrine dosing regimens
BRPI0513944A (pt) forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
UY27894A1 (es) Derivados de cinamida.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
BR0007864A (pt) Composto, e, uso de um composto
CL2022001692A1 (es) Compuestos activos frente a receptores nucleares
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
GT200600106A (es) Agentes endoparasiticidas
AR037756A1 (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.